Soleno Therapeutics, Inc.
SLNOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSoleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The $2.76B market capitalization puts SLNO squarely in mid-cap range for its industry. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.
Market Cap
$2.76B
Beta
-2.22
P/E (TTM)
27.47
P/E (Fwd)
-23.35
EPS (TTM)
$1.93
EPS (Fwd)
$-2.27
ROE
26.4%
ROA
12.1%
Cash
$255.6M
Total Debt
$54.3M
Free CF
$91.7M
52W Change
-29.4%
Annual Financials
Cash vs Debt
With $255.6M in cash and $54.3M in debt, SLNO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $91.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 26.4% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.1% further supports the picture of efficient asset utilization.
SLNO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, SLNO has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing SLNO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.